NR3C2 and hydrops fetalis: Mortality and morbidity reductions in patients with HF with reduced ejection fraction (HFrEF) are well documented for angiotensin-converting enzyme inhibitors (ACEis), angiotensin-receptor blockers (ARBs), angiotensin receptor–neprilysin inhibitors (ARNis), beta-adrenergic antagonists (βbs), mineralocorticoid-receptor antagonists (MRAs), and sodium glucose cotransporter-2 inhibitors (SGLT2is).4